<?xml version="1.0" encoding="UTF-8"?>
<p>HEV infection during pregnancy may lead to fulminant hepatic failure and is associated with a high mortality rate that ranges between 20% and 30% [
 <xref rid="B129-medicina-56-00206" ref-type="bibr">129</xref>,
 <xref rid="B130-medicina-56-00206" ref-type="bibr">130</xref>]. These results are of growing concern, especially in India and other endemic countries. The only preventive option is vaccines. Currently, two vaccines are being developed and one is already available in China [
 <xref rid="B7-medicina-56-00206" ref-type="bibr">7</xref>,
 <xref rid="B50-medicina-56-00206" ref-type="bibr">50</xref>]. The first is a recombinant vaccine which was tested in the US at Walter Reed Army Institute of Research; it was found to be safe and immunogenic [
 <xref rid="B131-medicina-56-00206" ref-type="bibr">131</xref>]. Further studies showed that the vaccine effectively prevented hepatitis E. The second vaccine, HEV239, which is now available in China, has had its phase 3 clinical trial in pregnant women [
 <xref rid="B132-medicina-56-00206" ref-type="bibr">132</xref>]. It does not have any negative fetal or maternal outcomes and prevents HEV infections. It can potentially reduce mortality and morbidity caused due to contracting HEV infection in pregnancy.
</p>
